Zika virus, a previously neglected mosquito-borne virus, is prompting worldwide concern because of its connection with congenital defects, Guillain-Barré syndrome, meningoencephalitis and myelitis in infected individuals. However, no specific antiviral therapy is available at present. In this study, we investigated the in vitro susceptibility of geographically and temporally distinct Zika viruses against the RNA polymerase inhibitors, favipiravir (T-705) and ribavirin.
Methods
The in vitro activity of each drug and a 1:1 mixture combination was assessed against five geographically and temporally distinct Zika strains by plaque reduction assay (PRA), the gold standard phenotypic method.
Results
We showed that both drugs exhibit in vitro inhibitory activity against five different Zika strains isolated in different years and continents, with mean 50% inhibitory concentration (IC50) values of 35 ±14 and 35 ±20 μM, respectively, by PRA. We did not observe a synergistic effect when both drugs were combined at the equimolar concentration (IC50 =33 ±11 μM).
Conclusions
These results indicate that T-705 has the potential to be used in patients with complicated diseases and/or those individuals presenting with significant comorbidities.
References
1.
KunoG., ChangG.J., TsuchiyaK.R., KarabatsosN., CroppC.B.Phylogeny of the genus Flavivirus.J Virol1998; 72: 73–83.
2.
DickG.W., KitchenS.F., HaddowA.J.Zika virus. I. Isolations and serological specificity.Trans R Soc Trop Med Hyg1952; 46: 509–520.
3.
DuffyM.R., ChenT.H., HancockW.T.Zika virus outbreak on Yap Island, Federated States of Micronesia.N Engl J Med2009; 360: 2536–2543.
4.
IoosS., MalletH.P., Leparc GoffartI., GauthierV., CardosoT., HeridaM.Current Zika virus epidemiology and recent epidemics.Med Mal Infect2014; 44: 302–307.
5.
ZanlucaC., MeloV.C., MosimannA.L., SantosG.I., SantosC.N., LuzK.First report of autochthonous transmission of Zika virus in Brazil.Mem Inst Oswaldo Cruz2015; 110: 569–572.
GowenB.B., WongM.H., JungK.H.In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.Antimicrob Agents Chemother2007; 51: 3168–3176.
10.
SmitherS.J., EastaughL.S., StewardJ.A., NelsonM., LenkR.P., LeverM.S.Post-exposure efficacy of oral T-705 (Favipiravir) against inhalational Ebola virus infection in a mouse model.Antiviral Res2014; 104: 153–155.
11.
MorreyJ.D., TaroB.S., SiddharthanV.Efficacy of orally administered T-705 pyrazine analog on lethal West Nile virus infection in rodents.Antiviral Res2008; 80: 377–379.
12.
JulanderJ.G., SmeeD.F., MorreyJ.D., FurutaY.Effect of T-705 treatment on western equine encephalitis in a mouse model.Antiviral Res2009; 82: 169–171.
13.
JochmansD., van NieuwkoopS., SmitsS.L., NeytsJ., FouchierR.A., van den HoogenB.G.Antiviral activity of favipiravir (T-705) against a broad range of paramyxoviruses in vitro and against human metapneumovirus in hamsters.Antimicrob Agents Chemother2016; 60: 4620–4629.
14.
Rocha-PereiraJ., JochmansD., DallmeierK., LeyssenP., NascimentoM.S., NeytsJ.Favipiravir (T-705) inhibits in vitro norovirus replication.Biochem Biophys Res Commun2012; 424: 777–780.
15.
ClinicalTrials.gov.Phase 3 efficacy and safety study of favipiravir for treatment of uncomplicated influenza in adults. 8 December 2013. (Accessed 15 September 2015.) Available from https://clinicaltrials.gov/ct2/show/NCT02008344.
16.
SissokoD., LaouenanC., FolkessonE.Experimental treatment with favipiravir for Ebola virus disease (the JIKI Trial): a historically controlled, single-arm proof-of-concept trial in Guinea.PLoS Med2016; 13: e1001967.
17.
ZmurkoJ., MarquesR.E., ScholsD., VerbekenE., KapteinS.J., NeytsJ.The viral polymerase inhibitor 7-deaza-2′-C-methyladenosine is a potent inhibitor of in vitro Zika virus replication and delays disease progression in a robust mouse infection model.PLoS Negl Trop Dis2016; 10: e0004695.
18.
HézodeC., ForestierN., DusheikoG.Telaprevir and peginterferon with or without ribavirin for chronic HCV infection.N Engl J Med2009; 360: 1839–1850.
19.
CooperA.C., BanasiakN.C., AllenP.J.Management and prevention strategies for respiratory syncytial virus (RSV) bronchiolitis in infants and young children: a review of evidence-based practice interventions.Pediatr Nurs2003; 29: 452–456.
20.
RattanabureeT., JunkingM., PanyaA.Inhibition of dengue virus production and cytokine/chemokine expression by ribavirin and compound A.Antiviral Res2015; 124: 83–92.
De ClercqE., LiG.Approved antiviral drugs over the past 50 years.Clin Microbiol Rev2016; 29: 695–747.
23.
KochharD.M., PennerJ.D., KnudsenT.B.Embryotoxic, teratogenic, and metabolic effects of ribavirin in mice.Toxicol Appl Pharmacol1980; 52: 99–112.
24.
VernekarS.K., QiuL., ZhangJ.5′-Silylated 3′-1,2,3-triazolyl thymidine analogues as inhibitors of West Nile virus and dengue virus.J Med Chem2015; 58: 4016–4028.
25.
PiretJ., GoyetteN., BoivinG.Novel method based on realtime cell analysis for drug susceptibility testing of herpes simplex virus and human cytomegalovirus.J Clin Microbiol2016; 54: 2120–2127.
26.
PerreaultM., MaltaisR., DutourR., PoirierD.Explorative study on the anticancer activity, selectivity and metabolic stability of related analogs of aminosteroid RM-133.Steroids2016; 115: 105–113.
HaydenF.G., CoteK.M., DouglasR.G.Jr.. Plaque inhibition assay for drug susceptibility testing of influenza viruses.Antimicrob Agents Chemother1980; 17: 865–870.
29.
MarklandW., McQuaidT.J., JainJ., KwongA.D.Broad-spectrum antiviral activity of the IMP dehydrogenase inhibitor VX-497: a comparison with ribavirin and demonstration of antiviral additivity with alpha interferon.Antimicrob Agents Chemother2000; 44: 859–866.
30.
MentréF., TaburetA.M., GuedjJ.Dose regimen of favipiravir for Ebola virus disease.Lancet Infect Dis2015; 15: 150–151.
